ストックスクリーナーアプリを入手
1.32
1.54%
0.02
アフターアワーズ：
1.26
-0.06
-4.55%
前日終値:
$1.30
開ける：
$1.3
24時間の取引高:
242.77K
Relative Volume:
1.19
時価総額：
$82.91M
収益：
-
当期純損益:
$-45.08M
株価収益率:
-1.8082
EPS:
-0.73
ネットキャッシュフロー:
$-33.68M
1週間 パフォーマンス:
+0.76%
1か月 パフォーマンス:
-2.94%
6か月 パフォーマンス:
-35.45%
1年 パフォーマンス:
-50.19%
1日の値動き範囲:
$1.29
$1.36
1週間の範囲:
$1.27
$1.37
52週間の値動き範囲:
$0.726
$3.17
Galectin Therapeutics Inc Stock (GALT) Company Profile
名前
Galectin Therapeutics Inc
セクター
電話
678-620-3186
住所
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
GALT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.32 | 82.91M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-08-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-13 | 開始されました | B. Riley FBR | Buy |
| 2017-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-10-19 | 開始されました | ROTH Capital | Buy |
| 2017-03-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | ダウングレード | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | ダウングレード | ROTH Capital | Buy → Sell |
| 2016-03-28 | 再開されました | H.C. Wainwright | Buy |
| 2015-09-21 | 開始されました | H.C. Wainwright | Buy |
| 2014-08-01 | ダウングレード | Aegis Capital | Buy → Hold |
| 2014-07-30 | 繰り返されました | MLV & Co | Buy |
| 2014-07-29 | 繰り返されました | MLV & Co | Buy |
| 2014-04-02 | 繰り返されました | MLV & Co | Buy |
| 2014-02-10 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-09 | 繰り返されました | Aegis Capital | Buy |
| 2013-12-03 | 開始されました | MLV & Co | Buy |
| 2013-08-19 | 繰り返されました | Aegis Capital | Buy |
すべてを表示
Galectin Therapeutics Inc (GALT) 最新ニュース
Northern Trust Corp Purchases 9,994 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc (NASDAQ: GALT) Stock: Investors Need To Know This - Stocksregister
Portal Hypertension Market Growth Projections 2023-2032: - openPR.com
MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Galectin Therapeutics (GALT) to Release Earnings on Thursday - MarketBeat
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | G - GuruFocus
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | GALT Stock News - GuruFocus
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - The Manila Times
Galectin Therapeutics Reports Q1 2025 Financial Results and Business Update - TradingView
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 26,047 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday - Defense World
Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - PR Newswire UK
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com Canada
Galectin Therapeutics Presents NAVIGATE Study Data Of Belapectin At EASL 2025 Congress - Nasdaq
Galectin Therapeutics (GALT) Reveals Promising NAVIGATE Study Re - GuruFocus
Belapectin shows promise in MASH cirrhosis trial - Investing.com Australia
Galectin Therapeutics Updates Corporate Presentation on Belapectin - TipRanks
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - The Manila Times
Galectin Therapeutics Inc. Reports Positive NAVIGATE Trial Results for Belapectin in MASH Cirrhosis Treatment - Nasdaq
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Position Boosted by JPMorgan Chase & Co. - Defense World
Renaissance Technologies LLC Decreases Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - The AM Reporter
9 Short Squeeze Stocks That Could Take Off - US News Money
Geode Capital Management LLC Has $1.12 Million Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
LPL Financial LLC Has $179,000 Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
RBC Capital Keeps Their Buy Rating on Brookfield Infrastructure (BIP) - The Globe and Mail
Will Alphabet Stock Keep Rising After Crushing Q1 Earnings Expectations? - The Globe and Mail
CEO.CA's Inside the Boardroom: Yukon Metals CEO Breaks Down Upcoming Drilling Plans for Star River Gold-Silver and AZ Copper Targets - The Globe and Mail
MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Game-Changing MASH Cirrhosis Treatment Results: New Clinical Data Shows Promise in Portal Hypertension - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World
HC Wainwright Analysts Boost Earnings Estimates for GALT - MarketBeat
FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat
Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Q2 EPS Forecast for Galectin Therapeutics Boosted by Analyst - The AM Reporter
HC Wainwright Analysts Raise Earnings Estimates for GALT - Defense World
HighTower Advisors LLC Buys Shares of 22,486 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Equities Analysts Set Expectations for GALT FY2029 Earnings - Defense World
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics (NASDAQ:GALT) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
HC Wainwright Reiterates “Neutral” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World
SPY ETF News, 4/3/2025 - The Globe and Mail
Galectin Therapeutics Reports Promising 2024 Results - TipRanks
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - The Manila Times
Galectin Therapeutics Inc (GALT) 財務データ
収益
当期純利益
現金流量
EPS
Galectin Therapeutics Inc (GALT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
40,000 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Sale |
0.88 |
13,654 |
12,044 |
26,346 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Option Exercise |
0.00 |
56,000 |
0 |
953,012 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Sale |
0.89 |
56,000 |
49,610 |
897,012 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
47,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Sale |
0.89 |
40,000 |
35,492 |
7,614 |
| Zordani Richard A. Jr. | Director |
Dec 24 '24 |
Buy |
0.82 |
10,000 |
8,164 |
42,083 |
| ELDRED KARY | Director |
Dec 24 '24 |
Buy |
0.82 |
13,469 |
11,045 |
63,682 |
| FREEMAN KEVIN D | Director |
Dec 24 '24 |
Buy |
0.81 |
10,000 |
8,134 |
44,769 |
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):